Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite that regulates various physiological and pathophysiological processes, including cancer, atherosclerosis, diabetes, and osteoporosis. It is produced by two sphingosine kinases, SphK1 and SphK2, and can act in an autocrine or paracrine manner. S1P primarily acts through five G protein-coupled receptors (S1PR1–S1PR5), but it also has intracellular targets involved in inflammation, cancer, and Alzheimer's disease. S1P signaling is complex, with important implications for therapeutic development. S1P is generated by the phosphorylation of sphingosine by SphK1 and SphK2. SphK1 is mainly cytosolic, while SphK2 is found in various intracellular compartments, including the nucleus and mitochondria. SphK2 in the nucleus regulates gene transcription by producing S1P, which inhibits histone deacetylases. SphK2 in mitochondria is involved in the assembly of the cytochrome oxidase complex. S1P is secreted extracellularly through transporters like ABCA1, ABCC1, and ABCG2, where it activates S1PRs, leading to "inside-out" signaling. S1P acts as an intracellular messenger by modulating apoptosis, cell survival, and gene expression. It interacts with proteins such as HDAC1/2, TRAF2, and PKCδ, influencing cellular processes like inflammation, immune responses, and cancer progression. S1P also plays a role in mitochondrial function and metabolism. In disease, S1P is involved in cancer by promoting tumor growth, angiogenesis, and metastasis. It also contributes to atherosclerosis by affecting vascular tone, inflammation, and plaque formation. In diabetes and obesity, S1P influences insulin resistance and metabolic disorders. In osteoporosis, S1P regulates osteoclast activity and bone homeostasis. S1P signaling is a promising therapeutic target, with inhibitors like FTY720 showing potential in treating multiple sclerosis and other diseases. Research continues to uncover the complex roles of S1P in health and disease, highlighting its importance in developing sphingolipid-based therapeutics.Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite that regulates various physiological and pathophysiological processes, including cancer, atherosclerosis, diabetes, and osteoporosis. It is produced by two sphingosine kinases, SphK1 and SphK2, and can act in an autocrine or paracrine manner. S1P primarily acts through five G protein-coupled receptors (S1PR1–S1PR5), but it also has intracellular targets involved in inflammation, cancer, and Alzheimer's disease. S1P signaling is complex, with important implications for therapeutic development. S1P is generated by the phosphorylation of sphingosine by SphK1 and SphK2. SphK1 is mainly cytosolic, while SphK2 is found in various intracellular compartments, including the nucleus and mitochondria. SphK2 in the nucleus regulates gene transcription by producing S1P, which inhibits histone deacetylases. SphK2 in mitochondria is involved in the assembly of the cytochrome oxidase complex. S1P is secreted extracellularly through transporters like ABCA1, ABCC1, and ABCG2, where it activates S1PRs, leading to "inside-out" signaling. S1P acts as an intracellular messenger by modulating apoptosis, cell survival, and gene expression. It interacts with proteins such as HDAC1/2, TRAF2, and PKCδ, influencing cellular processes like inflammation, immune responses, and cancer progression. S1P also plays a role in mitochondrial function and metabolism. In disease, S1P is involved in cancer by promoting tumor growth, angiogenesis, and metastasis. It also contributes to atherosclerosis by affecting vascular tone, inflammation, and plaque formation. In diabetes and obesity, S1P influences insulin resistance and metabolic disorders. In osteoporosis, S1P regulates osteoclast activity and bone homeostasis. S1P signaling is a promising therapeutic target, with inhibitors like FTY720 showing potential in treating multiple sclerosis and other diseases. Research continues to uncover the complex roles of S1P in health and disease, highlighting its importance in developing sphingolipid-based therapeutics.